Insmed Advances Four Parallel Phase 3 Studies for TPIP Dry Powder Inhaler

Four simultaneous pivotal studies running in parallel signal formulation and manufacturing commitments that dry powder inhaler developers will be tracking closely: Insmed is presenting its PALM Clinical Development Program at CHEST 2026, advancing treprostinil palmitil inhalation powder (TPIP) as a once-daily inhaled prostanoid across pulmonary arterial hypertension (PAH), pulmonary hypertension associated with interstitial lung disease (PH-ILD), progressive pulmonary fibrosis (PPF), and idiopathic pulmonary fibrosis (IPF).

The PALM program represents Insmed's largest parallel-running clinical effort to date. Three studies, PALM-PAH, PALM-ILD, and PALM-PPF, are already initiated; PALM-IPF is expected to begin in the first half of 2027. Combined enrollment is projected to exceed 2,000 patients across the four randomized, double-blind, placebo-controlled, multicenter trials, each running over a 24-week treatment period.

For formulation and process development teams, the program's architecture carries direct implications. TPIP is a dry powder inhalation formulation of a prostanoid, a class historically delivered via continuous intravenous infusion or multiple-daily inhaled doses. Achieving a stable, once-daily inhaled profile requires precise control of particle engineering, moisture content, and device-drug compatibility, all of which must be locked into a process validation package that can support multi-regional regulatory submissions across four indications simultaneously.

The Phase 2 data underpinning the PALM program demonstrated efficacy and safety signals in both PAH and PH-ILD populations, providing the clinical rationale for the pivotal step. Primary endpoints across the studies are anchored to change from baseline in 6-minute walk distance (6MWD) at Week 24, with secondary endpoints covering functional status, time to first clinical worsening, and pharmacokinetics, the latter being particularly relevant for QA and regulatory teams managing inhaled product variability across manufacturing lots.

For regulatory affairs leads, the breadth of the PALM program introduces a layered submission strategy: four indications, potentially divergent regional requirements, and a single drug-device combination that must satisfy 21 CFR Part 4 combination product frameworks alongside ICH Q8 and Q10 quality system expectations. Any manufacturing deviation or process drift identified during the trials carries amplified consequence when the same product supports four concurrent pivotal datasets.

Insmed's enrollment target of more than 2,000 patients across PALM-PAH, PALM-ILD, PALM-PPF, and PALM-IPF will serve as a measurable indicator of the program's operational execution as PALM-IPF initiation approaches in 2027.

Source: Insmed Incorporated via PR Newswire, October 15, 2026.